

New & Emerging Eczema Treatments



Living with a condition that has no 'cure' is difficult. Many people dream of finding that 'one thing' that will fix their eczema or prevent flare-ups but, the harsh reality is, it is a chronic and complex condition that is different for each individual. It is rare that 'one thing' is the answer.

Fortunately, medical researchers continue to strive for new treatments that provide relief from, what can be, an overwhelming experience. Be sure to ask your dermatologist about potential options and feel free to seek guidance from organisations such as Eczema Support Australia. Eczema Support Australia is committed to helping people living with eczema overcome difficulties and thrive in their community. As part of that pledge, here is an insight into emerging treatments that giving hope to many people living with eczema and their loved ones.



NEW TGA APPROVED TREATMENTS



Dupilumab (Dupixent®)*

This is given as an injection under the skin. It is a biologic that target an underlying source of inflammation and itch. Our eczema community campaigned and saw the successful listing of this medicine on the government's pharmaceutical subsidy scheme for patients aged 12 years and older with severe eczema not adequately controlled by topical therapies.

**PBS listed for severe eczema for 12 years and older.*

Crisaborole (Staqis®)

This is nonsteroidal topical medication used for the treatment of mild-to-moderate eczema. It blocks a certain substance in the body that triggers inflammatory symptoms of the condition. Crisaborole has been approved in Australia for patients from two years of age, with recent research indicating it may also be safely used from three months of age.

Upadacitinib (Rinvoq®)* Baricitinib (Olumiant®)

These are oral tablets that work by blocking signals involved in inflammation, also known as Janus kinase (JAK) inhibitors. These therapies have recently been TGA approved for patients 12 years and over with moderate to severe eczema.

**PBS listed for severe eczema for 12 years and older.*

OTHER EMERGING TREATMENTS

Other emerging therapies in Phase III or going through the TGA process include more oral JAK inhibitors and other Cytokine inhibitors. We will update this information resource regularly to reflect the exciting treatment developments in our 'Era of Eczema'.



- **PF-04965842**
An oral JAK1 inhibitor being investigated for use in moderate to severe atopic eczema.



- **Fezakinumab**
A monoclonal antibody that targets IL-22, that is thought to have a unique role in some of the epithelial abnormalities associated with atopic eczema.



- **Tradipitant**
An NK-1R antagonist being developed to reduce itch in patients with atopic eczema.

ABOUT US

Eczema Support Australia provides support to Australians who are significantly impacted by chronic eczema and other atopic or allergic conditions. The registered charity believes all families and individuals living with these chronic conditions deserve our community support and is guided by the three pillars of:

1. Advocacy 2. Connection 3. Information

